TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed unresectable Stage IIB or Stage III non-small cell lung cancer of any histologic-subtype appropriate for definitive concurrent chemotherapy and radiation as determined by multi-disciplinary assessment; all detectable tumor should be encompassable by radiation therapy fields, including both the primary tumor and the involved regional lymph nodes~* Granulocytes \>= 1500/ul~* Platelets \>= 100,000/ul~* Bilirubin \< 1.5 mg/dl~* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) \< 2 upper limit of normal (ULN)~* Creatinine clearance must be \> 60ml/min~* Eastern Cooperative Oncology Group (ECOG) 0 to 1~* Weight loss =\< 5% in the previous six months unless weight loss is intentional (per judgment of study medical doctor \[MD\])~* Forced expiratory volume in one second (FEV1) must be \>= 1.0 L~* Patients must sign a study-specific informed consent form prior to study entry~* Patients must have measurable disease on the 3D planning computed tomography (CT)~* Patient must have a completed 3D plan and the attending physician must have reviewed and approved the dose volume histograms as follows: total lung volume percentage receiving at least 20 Gy (V20) =\< 35%, and mean lung dose =\< 20 Gy~Exclusion Criteria:~* Mixed histology or undifferentiated small cell carcinoma, any stage~* Concurrent malignancy except non-melanomatous skin cancer or prior cancer if disease-free for one year or more~* Patients with malignant pleural effusions or significant pericardial effusions~* Pregnant or lactating females~* Severe neuropathy greater than or equal to grade 2~* Severe sensorineural hearing loss greater or equal to grade 2~* No clinically significant history of cardiac disease, (i.e. uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the past year, or cardiac ventricular arrhythmias requiring medication)~* Any significant or severe medical conditions or psychiatric or social conditions that would preclude adherence to the protocol or compliance with study treatments

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (radiation therapy and chemotherapy) (Type: EXPERIMENTAL): Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Moderate-to-vigorous Physical Activity for Glycemic Control in Patients With Gestational Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* gestational diabetes mellitus~* singelton pregnancy~* 18 years old or older~* no medical contraindications to exercise~Exclusion Criteria:~* multiple gestation~* non-English speaking~* unable to exercise~* preexisting diabetes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Moderate-to-vigorous intensity exercise (Type: EXPERIMENTAL): Moderate-to-vigorous intensity exercise three times per day for three weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Blood for Full-thickness Macular Hole

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary and recurrent holes~Exclusion Criteria:~* Lamellar and pseudoholes

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Utilizing autologous whole blood for the full thickness macular hole (Type: EXPERIMENTAL): It is an interventional study by performing pars-plana vitrectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging To Predict Outcomes In Aortic Aneurysms

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with an abdominal aortic aneurysm \>40 mm~Exclusion Criteria:~1. Any medical history or clinically relevant abnormality identified on the screening medical examination, vital sign measurement, or clinical laboratory examination that is deemed by the principal investigator and/or designee to make the subject ineligible for inclusion.~2. Subjects with planned AAA surgery.~3. Renal impairment with eGFR of \<30 mls/min at screening, history of kidney transplant or history of contrast nephropathy.~4. Women of child-bearing potential without contraception,~5. Collagen-vascular disease.~6. Inability to undergo magnetic resonance or computed tomography scanning,~7. Contraindication to MRI scanning (as assessed by local MRI safety questionnaire) which includes but not limited to:~   * Intracranial aneurysm clips (except Sugita) or other metallic objects,~  * History of intra- orbital metal fragments that have not been removed,~  * Pacemakers, implantable cardiac defibrillators and non-MR compatible heart valves,~  * Inner ear implants,~  * History of claustrophobia in MR.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abdominal Aortic Aneurysms (Type: None): Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of HYPNOsis Masks During Botulinum TOXin Injections in Idiopathic Overactive Bladder(HypnoTox)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Woman with non-neurological overactive bladder, confirmed by urodynamic assessment and cystoscopy, having resisted a well-conducted pharmacological treatment (trials of various anticholinergics).~* Age over 18 years~* Having understood the study and agreed to participate (signing of informed consent)~* Beneficiary of a health insurance plan~Exclusion Criteria:~* Neurological patient: tetraplegic, paraplegic, multiple sclerosis for a reliable pain assessment~* Patients who have already been injected with botulinum toxin in the treatment of this pathology.~* Psychiatric pathology at risk of decompensation with self-hypnosis~* Patients who are difficult to assess because of a psychological disorder that does not allow them to answer questionnaires and pain assessment scales~* Patients under court protection, guardianship or curatorship

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control arm (Type: NO_INTERVENTION): conventional anaesthesia~The botulinum toxin injection procedure will be carried out in the standard way, according to the recommendations applicable in France, and after local anaesthesia.
- interventional arm (Type: EXPERIMENTAL): conventional anaethesia and use of the self-hypnosis mask~The mask and the helmet are positioned and activated 10 minutes before the procedure, with the travel to india programme chosen because it was developed for pain management and its duration is compatible with the procedure (25 minutes).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Carriage Rates in Resident Physicians

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Study subjects will be newly appointed residents at the OU medical center~Exclusion Criteria:~* Previous MRSA infection~* Current use of mupirocin

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- MRSA surveillance (Type: None): Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 1 diabetes (according to American Diabetes Association \[ADA\] criteria) within100 days of enrollment~* Positive for one or more autoantibodies (anti-glutamic acid decarboxylase \[GAD\], anti-insulin, or IA-2 autoantibodies)~* Peak stimulated C-peptide level \>0.4 pmol/mL or \>1.2ng/mL following an MMTT~* Serologic evidence of prior Epstein-Barr virus (EBV) infection (EBV seropositive)~* Willing to use acceptable forms of contraception~Exclusion Criteria:~* Any sign of active infection (e.g., hepatitis, tuberculosis, EBV, cytomegalovirus (CMV), or toxoplasmosis) at screening~* Positive for human immunodeficiency virus (HIV), tuberculosis, or hepatitis B surface antigen (HBsAg) at screening~* Prior history of any significant cardiac disease, such as congestive heart failure, arrhythmia, or structural defects, or suspicion thereof~* Use of glucocorticoids in the 28 days prior to study entry; or topical use of glucocorticoids~* Use of diabetes medications (other than insulin) that may affect glucose homeostasis, such as metformin, sulfonylureas, thiazolidinediones, or amylin~* Evidence of liver dysfunction~* Evidence of kidney disease~* Pregnancy or plan to become pregnant~* Leukopenia (\<3,000 leukocytes/µL), neutropenia (\<1,500neutrophils/µL), lymphopenia (\<800 lymphocytes/µL), or thrombocytopenia (\<125,000 platelets/µL).~* Prior treatment with rabbit ATG or known hypersensitivity or exposure to rabbit sera-derived products~* Vaccination with a live virus within the last 6 weeks before enrollment~* Prior or current therapy that is known to cause a significant, ongoing change in the course of T1DM or immunologic status~* Any condition that may compromise study participation or may confound the interpretation of the study results

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Antithymocyte globulin (Type: EXPERIMENTAL): This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
- Placebo (Type: PLACEBO_COMPARATOR): This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and above (adult population)~* All open and closed tibial plateau fractures~Exclusion Criteria:~* 17 years of age and less (pediatric population)~* Quadriplegic patients~* Vascular Injury to Extremity~* Ipsilateral femur fractures~* Ipsilateral Hip fractures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anterior pin placement (Type: EXPERIMENTAL): Anterior pin placement
- Lateral pin placement (Type: EXPERIMENTAL): Lateral pin placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parkinson's disease per Queens Square criteria~* Appropriate DBS candidate for multi-disciplinary team consensus~* Age 18 - 85 years of age~* Motor skills allowing for capability to complete evaluations~* Medically cleared for undergoing anesthesia and DBS surgery~Exclusion Criteria:~* Dementia per DSM-V criteria~* Medical or other condition precluding MRI~* History of supraspinal CNS disease other than PD~* Alcohol use of more than 4 drinks per day~* Pregnancy~* History of suicide attempt~* Currently uncontrolled clinically significant depression (BDI\>20)~* History of schizophrenia, delusions, or currently uncontrolled visual hallucinations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Awake DBS Surgery (Type: ACTIVE_COMPARATOR): Deep brain stimulation surgery: Parkinson's patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intra-operative stimulation
- Asleep DBS Surgery (Type: ACTIVE_COMPARATOR): Deep brain stimulation surgery:Parkinson's patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of NSCLC with a protein that acts as a kind of brake to keep the body's immune responses under control called Programmed Death Ligand-1 (PD-L1) Tumor Proportion Score (TPS) ≥ 1% and no known alterations in driver genes epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or receptor tyrosine kinase (ROS1).~2. Retrospective cohort: subjects must consent to provide genetic data from previous whole exome sequencing (WES) in the form of FASTQ/BAM files (files that represent aligned genetic sequences) for creation of plasma ctDNA panels.~3. Prospective cohort: Subjects must consent to provide available archived tumor and blood for WES (matched tumor and normal) for creation of plasma ctDNA panels. The tumor sample must be from a site that was not previously irradiated or has progressed after radiation.~4. Ability to understand and the willingness to sign a written informed consent document.~5. Willing to comply with clinical trial instructions and requirements.~6. Both men and women of all races and ethnic groups are eligible for this trial~Exclusion Criteria:~1. Age \<18 years~2. Known history of autoimmune disease or other medical conditions that would preclude safe treatment with pembrolizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prospective Sample Collection (Type: None): Prospective sample collection from participants treated with pembrolizumab monotherapy at Columbia University Irving Medical Center under standard of care treatment. Prospective cohort subjects must consent to provide available archived tumor and blood for whole exome sequencing (WES) (matched tumor and normal) for creation of plasma ctDNA panels. The tumor sample must be from a site that was not previously irradiated or has progressed after radiation.
- Retrospective Sample Collection (Type: None): Retrospective sample collection from participants that consent to provide genetic data from previous whole exome sequencing (WES) in the form of files for creation of plasma ctDNA panels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age ≥ 18 years~2. Newly diagnosed, AL amyloidosis treatment naïve~3. Bone marrow consistent with plasma cell dyscrasia~4. Confirmed diagnosis of AL amyloidosis~5. Cardiac involvement~6. Planned first-line chemotherapy contains a proteasome-inhibiting agent administered weekly~7. Adequate bone marrow reserve, hepatic and renal function~Key Exclusion Criteria:~1. Non-AL amyloidosis~2. Meets diagnostic criteria for symptomatic multiple myeloma~3. Subject is eligible for and plans to undergo ASCT~4. History of Grade ≥ 3 infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NEOD001 (Type: EXPERIMENTAL): 24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered as a 250 mL bag of normal saline once every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Risk Categories and Attaining LDL-C Targets in Middle Eastern Adults Aged 30-55 Years of Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18-55 y~* Individuals can give a history of the presence or absence of ASCVD and its risk factors~Exclusion Criteria:~* Age below 18 or older than 55~* Refusal of inability to give history on ASCVD and its risk factors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Protection of Rectum From High Radiation Doses Using a Spacer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* prostate cancer patients with planned low-dose brachytherapy for the treatment of prostate cancer~Exclusion Criteria:~* not willing to participate this study

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Diluted spacer (Type: EXPERIMENTAL): Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
- Non-diluted spacer (Type: ACTIVE_COMPARATOR): Single dose of DuraSeal product injected between rectum and prostate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Self-Sampling for Human Papillomavirus (HPV) at Well Women Appointments

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30-65 Years~* Penn State Health, Family and Community Medicine, patient attending a well-woman visit~* Able to collect the sample within two weeks of visit~* Female~* Intact cervix~* Speaks, reads, or writes in English~Exclusion Criteria:~* Pregnancy~* Cognitively Impaired~* Incarcerated~* Complete hysterectomy~* History of cervical treatment for abnormal Pap/HPV test (cryotherapy, LEEP)

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Self-Sampling Kit (Type: EXPERIMENTAL): Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues